1. Introduction {#sec0005}
===============

The hippocampus, like the rest of the brain, changes in volume throughout the human lifespan and is subject to factors such as age ([@bib0110]), psychiatric health ([@bib0180]) and altered circulating endogenous factors, such as hormones ([@bib0025]). The hippocampus is not a homogeneous structure and is composed of multiple subfields, each with a different cellular makeup, function and associated circuitry ([@bib0225]). Cellular mediators of hippocampal volume changes include altered cell death, cell size, and branching of both neurons and astroglia ([@bib0105]). Additionally, adult hippocampal neurogenesis (AHN) provides a unique region-specific mechanism contributing to variability in the volume and plasticity of the dentate gyrus, specifically ([@bib0385]).

Research has shown that the endocrine system is partly involved in the regulation of hippocampal volume and function, indicating roles for estrogens (i.e. estradiol), androgens (i.e. testosterone), progestogens (i.e. progesterone) and peptide hormones (i.e. prolactin) ([@bib0160]). A variety of cross-sectional, intervention and longitudinal studies have shown that these circulating reproductive hormones often correlate with hippocampal volume ([@bib0025]; [@bib0030]; [@bib0055]; [@bib0270]; [@bib0360]). The mammalian hippocampus has the potential to be a direct target of reproductive hormones as it expresses the receptors necessary for signal transduction, namely the estrogen receptors 1 and 2, the androgen receptor, progesterone receptor and prolactin receptor ([@bib0070]; [@bib0255]; [@bib0370]; [@bib0400]). In the hippocampus, downstream signaling pathways of these receptors have the potential to drive volume changes through their known effects on AHN, dendritic morphology and the survival of neurons ([@bib0160]; [@bib0245]).

The volume of the hippocampus and its subfields have been linked to a wide range of neurological and psychiatric disorders. Reduced hippocampal volume is observed in anxiety, schizophrenia, Alzheimer's disease, and the aged brain in general ([@bib0015]; [@bib0110]; [@bib0410]; [@bib0195]; [@bib0350]; [@bib0355]). A loss of hippocampal volume is a commonly reported feature of depressive disorders ([@bib0075]; [@bib0340]; [@bib0365]) and is not only associated with the presence of the disease, but volume reductions often correlate with increased disease severity or recurrence ([@bib0340]; [@bib0395]). It is hypothesized that these volume reductions mediate disturbances in cognitive function (e.g. negative affect, ruminating thoughts) which in turn, increase risk for depressive disorders ([@bib0240]). In addition, individual hippocampal subfields exhibit independent volumetric changes in a variety of contexts. For example, atrophy of the dentate gyrus and cornu ammonis regions is commonly observed in major depressive disorder (MDD) ([@bib0205]) and schizophrenia ([@bib0185]), but only schizophrenia patients exhibit smaller subiculum regions ([@bib0185]).

Changes to circulating reproductive hormones have also been linked to the development of depressive disorders in a wide range of human studies ([@bib0020]; [@bib0135]; [@bib0200]; [@bib0335]; [@bib0435]). Interestingly, females have an almost two-fold greater risk of developing MDD relative to men ([@bib0060]; [@bib0220]), which is thought to be in part due to hormonal differences and the prevalence of reproductive-related depressive disorders such as postpartum depression (PPD) ([@bib0230]). Due to the aforementioned link between reproductive hormones and the hippocampus, this brain region is a promising mediator linking differences in reproductive hormones to risk of depression. For instance, in the peripartum period, alongside an increased risk of depression diagnosis and robust hormonal changes ([@bib0280]; [@bib0345]; [@bib0380]), there are observable alterations to hippocampal volume in rodents, which return to normal in the weeks following parturition ([@bib0155]).

Previous studies have mainly focused on the correlation between reproductive hormones and whole hippocampal volume; testing the relationship at a single point in time ([@bib0025]; [@bib0270]). Although such studies are insightful, they are limited for three key reasons. Firstly, with correlations alone, it is not possible to discern whether reproductive hormones are causally affecting hippocampal volume, or whether reproductive hormones and hippocampal volume are impacted by an independent environmental factor (e.g. diet or stress). Secondly, as reproductive hormones are highly dynamic, it can be difficult, particularly in smaller studies with single measurements, to generate a stable quantitative measure that adequately captures inter-individual variation in hormone levels necessary to assess correlations with the hippocampus. Finally, until now, only whole hippocampal volumes have been assessed, but as certain areas of the hippocampus contain stem cells that give rise to new mature neural cells during AHN, it would be beneficial to evaluate individual subfield volumes in order to test whether the 'neurogenic niches' mediate volume differences in response to reproductive hormones, or whether it is mediated by other areas of the hippocampus.

To address these limitations, we employed a Mendelian randomization design, which uses genetic information to infer the presence of a causal relationship between two traits. We tested whether polygenic risk scores (PRSs) for reproductive hormones predict right or left hippocampal volumes; hippocampal subfield volumes; and subsequently MDD or PPD case-control status. This approach utilizes hormone-specific PRSs as stable genetic predictors of inter-individual variation in reproductive hormone levels. To achieve this, we used genome-wide association study (GWAS) summary statistics from 2906 individuals within the TwinsUK cohort, which has previously identified single nucleotide polymorphisms (SNPs) associated with circulating reproductive hormones, including estradiol, testosterone, progesterone and prolactin ([@bib0320]). To identify links with hippocampal volume and depressive disorders we used the European RADIANT cohort consisting of 176 PPD cases, 2772 MDD cases and 1588 control participants, for which there is also a neuroimaging subset of 111 individuals. We identified the best combination of SNPs from a range of p-value thresholds obtained from each reproductive hormone GWAS, that predicted right or left hippocampal volume in our neuroimaging sample. Next, we tested the effect of this best-fit PRS on the 12 hippocampal subfield volumes. As these 111 individuals represented a subset of the larger depression case-control study, our final aim was to test whether this best-fit PRS for predicting hippocampal volumes, further predicted PPD or MDD in the full RADIANT cohort.

2. Materials and methods {#sec0010}
========================

2.1. RADIANT sample {#sec0015}
-------------------

RADIANT is an umbrella term for three studies which sought to understand genetic risk for MDD and factors aﬀ ;ecting response to antidepressant treatments ([@bib0235]); this comprised of the Depression Network (DeNT) study ([@bib0130]), the Depression Case-Control (DeCC) study ([@bib0090]) and the Genome-Based Therapeutic Drugs for Depression (GENDEP) study ([@bib0405]). As the DeNT study was composed of sibling pairs, only one sibling from each family were randomly included in genetic studies ([@bib0235]). The DeCC and DeNT studies only recruited individuals who had experienced recurrent depression. While the GENDEP study did not aim to solely recruit recurrent depression cases, 77.3% of cases were in fact recurrent. Therefore, the entire RADIANT cohort contains a majority of recurrent depression cases (94.6%). All participants were interviewed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) interview ([@bib0425]) focusing on their two most severe depressive episodes (if applicable). Participants were excluded if they, or a first-degree relative, had ever experienced mania, hypomania, bipolar disorder, schizophrenia, schizo-affective disorder, intravenous drug dependence, substance-induced mood disorder or mood disorders secondary to medical illness or medication. A total of 2772 MDD cases, 176 PPD cases and 1588 unaffected controls were available from these studies for the work outlined here ([Table 1](#tbl0005){ref-type="table"}).Table 1Demographic details of the neuroimaging subset and depressed patients and controls in the whole RADIANT cohort.Table 1*Neuroimaging subsetEntire RADIANT cohortControlPPDMDDN*11115881762772*Female (N, %)*67 (60.4)993 (62.5)176 (100)1901 (68.6)*Age (mean, SD)*50.0 (8.1)42.4 (13.0)41.6 (9.5)46.9 (12.3)*Depressed (N, %)*58 (47.7)------*Antidepressants (N, %)*44 (39.6)------*Handedness (N, %)*------ Right94 (84.7)------ Left13 (11.7)------ Ambidextrous3 (2.7)------[^1]

Major depressive disorder cases: Participants were classified as MDD cases if they had experienced at least one episode of major depression of at least moderate severity as defined by the Diagnostic and Statistical Manual of Mental Disorders 4th edition operational criteria (DSM-IV) ([@bib0005]) or the International Classification of Diseases 10th edition operational criteria (ICD-10) ([@bib0430]) for unipolar depression. For the purpose of this study we excluded MDD patients who met further criteria for PPD, as we considered these individuals separately. MDD cases were 68.6% female, with an age range 18--67 (mean = 46.9, S.D. = 12.3).

Postpartum depression cases: From the MDD cases identified within RADIANT (where data were available), cases of PPD were identified using the list of threatening experiences questionnaire (LTE-Q). The LTE-Q is a 12-term self-reported questionnaire which measures the occurrence of stressful life events in the 6 months prior to depression onset, to which childbirth has been added ([@bib0065]; [@bib0130]). PPD cases were identified as females who had experienced either of their two most severe major depressive episodes within 6 months of childbirth. PPD cases were 100% female, with an age range of 20--67 (mean = 41.6, S.D. = 9.5).

Control participants: Control participants were screened using a modified version of the Past History Schedule ([@bib0250]) for any psychiatric disorder throughout their life. They were excluded if they, or a first-degree relative had suffered from depression or any other psychiatric disorder. Control participants were 62.5% female, with an age range of 18--89 (mean = 46.9, S.D. = 12.3).

Neuroimaging subset: For a subset of the participants described above (N = 111), neuroimaging data was available. Demographics of participants with both genotype and neuroimaging data are described in [Table 1](#tbl0005){ref-type="table"}. This subset was 67% female with an age range of 26--66 years old (mean = 50.0, S.D. = 8.1). 58% of the neuroimaging cohort were depressed cases (either MDD or PPD) and all had experienced recurrent depression. 44% had taken pharmacological antidepressants in the 6 months preceding the MRI scan. The majority of the cohort were righthanded (94%). In addition to the exclusion criteria described above, participants were excluded from neuroimaging analysis if they had previously experienced any severe head trauma, neurological condition or any other contraindications to magnetic resonance scanning.

2.2. RADIANT genetic data {#sec0020}
-------------------------

Genotyping data from the RADIANT cohort was already available and have been used in previous publications ([@bib0235]). Genomic DNA was extracted from blood and buccal swabs as described previously ([@bib0150]). DNA samples were genotyped using the Illumina Human610-Quad bead chip (Illumina, Inc., San Diego, CA, USA) at the Centre National de Genotypage (Evry Cedex, France). Single nucleotide polymorphism (SNP) information was available as PLINK files ([@bib0295]).

2.3. RADIANT MRI data {#sec0025}
---------------------

MRI data had been collected from a subset of RADIANT, as described previously ([@bib0095], [@bib0100]). Magnetization-Prepared Rapid Gradient Echo (MP-RAGE) T1-weighted scans were acquired using a 1.5 T General Electric Signa MR Imaging System (General Electric, Milwaukee, Wisconsin, USA) from participants in the sagittal plane using the parameters: echo time = 3.8 ms, repetition time = 8.592 ms, inversion time = 1000 ms, flip angle = 8°, voxel dimensions = 0.939 × 0.937 ×1.2 mm, matrix size 192 × 192, field of view = 240, slice thickness = 1.2 mm, number of slices = 180.

All T1-weighted images were visually inspected for motion artefact, wrap-around and grey/white contrast; no data were excluded. Automated whole brain segmentation, cortical reconstruction and hippocampal subfield segmentation were carried out using FreeSurfer v6.0 (Massachusetts General Hospital, Harvard Medical School; <http://surfer.nmr.mgh.harvard.edu>) ([@bib0140]; [@bib0210]). Hippocampal subfield volumes were visually inspected and no manual edits were necessary. Volumes were also assessed so that outliers could be identified, although no data were excluded based on these measures. The hippocampal subfields identified using this segmentation method and included in this study are as follows: parasubiculum, presubiculum, subiculum, cornu ammonis 1 (CA1), cornu ammonis 2/3 (CA2/3), cornu ammonis 4 (CA4 or hilus), granule cell layer of the dentate gyrus, molecular layer of the dentate gyrus, fimbria, hippocampal-amygdala-transition area (HATA), hippocampal tail and hippocampal fissure. All subfields represent regions of grey matter except for the hippocampal fissure which is a sulcus residing between the dentate gyrus and subiculum.

2.4. Polygenic risk scoring {#sec0030}
---------------------------

A polygenic risk score (PRS) is a number which represents an individual's genetic load of risk alleles for a certain base trait. Here we created PRSs for estradiol, progesterone, prolactin and testosterone separately for each individual in the RADIANT cohort. PRSs for each reproductive hormone were generated using summary statistics from the largest GWAS for plasma reproductive hormones to-date, consisting of 2906 individuals from the Twins UK cohort ([@bib0320]). This GWAS used a sample consisting of predominantly female participants, and excluded individuals undergoing any hormonal therapies. The original GWAS analysis took into account the age, sex, BMI, stage of menstrual cycle and menopausal status of the participants.

PRSice version 1.25 software was used to implement a pipeline of processes common in PRS creation ([@bib0125]). Firstly, SNPs present in only the base GWAS or target RADIANT cohort were removed. Ambiguous (A/T or C/G) SNPs were also removed. SNPs in linkage disequilibrium (r^2^\>0.1) were removed using a process called clumping, leaving a single SNP in each 250 kb LD window with the smallest p-value from the GWAS. Clumping was preferred over pruning in order to retain SNPs across the entire genome. The remaining SNPs were used to calculate PRSs for eight p-value thresholds (0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5). At each p-value threshold, the SNPs that fell below this threshold in the GWAS summary statistics were identified, and the number of risk variants (0, 1 or 2) that an individual carried was multiplied by the logarithm of the odds ratio for that variant. The sum of all these values gives the PRS for an individual and the process is repeated for all the individuals in the cohort and for all hormones.

2.5. Statistical analyses {#sec0035}
-------------------------

### 2.5.1. PRSs and hippocampal volumes {#sec0040}

Left and right whole hippocampus and hippocampal subfield volumes were checked for normality using histograms and Kolmogorov-Smirnov and Shapiro-Wilk normality tests ([@bib0415]), with non-normal volumes undergoing log-transformation. Subsequently, volumes were adjusted for intracranial volume, sex, age and depression case-control status by taking the standardized residuals (z-scores) using SPSS v.24. The effects of handedness in the whole cohort, and current antidepressant use (last 6 months) amongst depressed cases, was tested, and found not to significantly affect either right or left hippocampal volumes (p\>0.05).

We first tested the relationships between PRSs for each reproductive hormone, and either adjusted left or right hippocampal volume, using regressions in PRSice ([@bib0125]). In each regression we included seven population covariates to correct for population structure. These population covariates were the top seven components derived using multi-dimensional scaling in PRSice. We tested the predictive power of PRSs derived from SNPs under eight p-value thresholds (p = 0.001, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4 and 0.5), in order to determine the optimal p-value threshold and "best fit" PRS for each hormone and hemisphere combination. For each hormone and hemisphere combination, we corrected for the number of p-value thresholds tested using the Benjamini-Hochberg correction ([@bib0035]) and a false discovery rate of 10%.

Where a PRS for a reproductive hormone explained a significant proportion of the variance in either whole left/right hippocampal volume, we tested whether the same best fit PRS predicted the volume of its 12 constituent subfields. This was again performed using PRSice software, with the same seven population covariates, as described above. We corrected for the number of subfields tested using the Benjamini-Hochberg correction with a false discovery rate of 10%.

### 2.5.2. PRS and depression case-control status {#sec0045}

Lastly, once we had identified a hormone-related PRS which significantly predicted hippocampal volume, we tested whether the same PRS was associated with PPD or MDD case-control status in the wider RADIANT cohort. Binary logistic regressions, including sex-stratified regressions were performed for each depression subtype in PRSice, covarying for seven population covariates, derived using multi-dimensional scaling in PRSice, with sex included as a covariate where appropriate (i.e. when both males and females were included in the same analysis).

3. Results {#sec0050}
==========

3.1. Polygenic risk for circulating estradiol is associated with whole hippocampal volume {#sec0055}
-----------------------------------------------------------------------------------------

We created PRSs for plasma estradiol, testosterone, progesterone and prolactin at eight p-value thresholds and tested for their association with either right or left whole hippocampal volume. After correcting for multiple p-value thresholds, only the PRS for estradiol was found to be significantly associated with whole hippocampal volume ([Table 2](#tbl0010){ref-type="table"}). The best-fit estradiol PRS (using p~thresh~ = 0.1 for both hemispheres) was negatively associated with both right (B = −2498.209, SE = 919.795, p = 0.008, R^2^ = 0.062) and left (B = −2528.269, SE = 928.911, p = 0.008, R^2^ = 0.064) hippocampal volumes, and survived our multiple testing criteria (q \< 0.1) ([Table 2](#tbl0010){ref-type="table"}, [Fig. 1](#fig0005){ref-type="fig"}). The best fit PRSs for prolactin, testosterone and progesterone were not significantly associated with either right or left whole hippocampal volume.Table 2Table showing the results of regressions that tested the predictive ability of best-fit PRS for all reproductive hormones on left and right whole hippocampal volumes.Table 2HippocampusOptimal p-value thresholdnSNPsp-valueq-valueR^2^βSEEstradiol Right0.1273890.008\*0.0510.062−2498.209919.795 Left0.1273890.008\*0.0400.064−2528.269928.911Progesterone Right0.0012750.1200.2860.022−112.95772.091 Left0.0123400.0720.2530.030−370.014203.569Prolactin Right0.0125200.3390.7350.008370.970386.164 Left0.4541980.0550.1760.0345977.3053083.026Testosterone Right0.0599530.0960.5430.025−1274.616758.934 Left0.0599530.1380.5860.020−1148.102768.731[^2]Fig. 1A&B) Output from PRSice displaying the results of regressing the estradiol PRS against the (A) left and (B) right hippocampal volume at the range of p-value thresholds tested (x-axis). A combination of SNP information under p=0.1 significantly best predicted both left and right hippocampal volumes. Variance explained (R^2^) is indicated on the y-axis and uncorrected p-values are indicated above each bar. C&D) Scatterplots demonstrating significant negative correlations between the best-fit PRS for estradiol levels (z-scores; adjusted for 7 population covariates derived from multidimensional scaling to control for population stratification) and whole hippocampal volumes (z-scores; adjusted for intracranial volume, age, sex, case-control status) for the (C) left and (D) right hemispheres. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).Fig. 1

3.2. Polygenic risk for circulating estradiol is associated with hippocampal subfields {#sec0060}
--------------------------------------------------------------------------------------

Next, we investigated the association between the best-fit estradiol PRS and hippocampal subfield volumes. As with the whole hippocampus, the estradiol PRS was associated with the volume of multiple hippocampal subfields ([Table 3](#tbl0015){ref-type="table"}). After multiple testing correction, the estradiol PRS was significantly associated with the right and left subiculum, CA1, molecular layer of the dentate gyrus, granule cell layer of the dentate gyrus, CA2/3 and CA4 regions ([Table 3](#tbl0015){ref-type="table"}). It was also unilaterally associated with the volume of the left hippocampal tail and right hippocampal fissure. A graphical representation of the associations between the estradiol PRS and all hippocampal subfield volumes can be observed in [Fig. 2](#fig0010){ref-type="fig"}. For all significant relationships, a PRS indicative of higher estradiol levels was associated with a reduced volume.Table 3Table showing the results of regressions that test the predictive ability of best-fit PRS for estradiol, on hippocampal subfield volumes.Table 3SubfieldUncorrected p-valueq-valueR^2^βSERight hippocampus CA10.026\*0.0630.043−2120.714941.310 CA2/CA30.051\*0.0870.035−1870.666945.199 CA40.009\*0.0340.060−2451.741919.490 Granule cell layer0.010\*0.0340.058−2398.323916.184 Molecular layer0.004\*0.0340.068−2690.309912.037 Subiculum0.011\*0.0340.053−2394.581928.655 Presubiculum0.1470.1960.016−1399.802958.286 Parasubiculum0.7840.9400.001−268.661975.640 Hippocampal tail0.0850.1270.028−1657.922952.250 Hippocampal fissure0.043\*0.0860.027−1952.554952.076 Fimbria0.9960.9960.000−4.561945.580 HATA0.9620.9960.00045.173941.158Left hippocampus CA10.025\*0.0600.045−2129.952935.255 CA2/CA30.038\*0.0750.040−1995.406950.145 CA40.002\*0.0130.082−2860.001914.747 Granule cell layer0.001\*0.0110.094−3062.294898.117 Molecular layer0.003\*0.0130.077−2774.238922.557 Subiculum0.016\*0.0490.052−2284.700934.863 Presubiculum0.4160.5540.006−787.328963.220 Parasubiculum0.4730.5680.005679.613944.346 Hippocampal tail0.044\*0.0750.038−1935.976946.996 Hippocampal fissure0.1050.1580.025−1581.2968.023 Fimbria0.5250.5730.004619.043971.228 HATA0.9940.9940.000−7.131967.600[^3]Fig. 2Visual representation of the predictive ability of the best-fit PRS for estradiol on hippocampal subfield volume. A. Example sagittal, axial and coronal cross-sections of the human hippocampus segmented from an example MRI image using FreeSurfer and colour-coded to indicate each hippocampal subfield. B. For each hemisphere and subfield combination, the results of the linear regression are represented in a scale of dark blue (β=−0.4), through white (β=0), to dark red (β=0.4) for the beta coefficient, and green to white for the FDR-corrected q-value. Relationships which did not survive the FDR correction are represented in grey (q\>0.1). The six figures to the left relate to the left hippocampus, and the six figures to the right relate to the right hippocampus. Relative hippocampal subfield structure is for visualisation only and is not representative of all participants. The numerical data is available in [Table 3](#tbl0015){ref-type="table"}.Fig. 2

3.3. Polygenic risk for circulating estradiol does not predict depression case-control status {#sec0065}
---------------------------------------------------------------------------------------------

Finally, we tested whether the best-fit PRS for estradiol levels, identified above, predicted the risk of depressive disorders. The estradiol PRS was not associated with PPD case-control status or MDD case-control status, including in sex-stratified analyses (p\>0.05; [Table 4](#tbl0020){ref-type="table"}).Table 4Table showing the results of regressions that test the predictive ability of best-fit PRS for estradiol and hippocampal volume on case control status for either postpartum depression of major depressive disorder in males and females. All regression analyses include seven population covariates, derived from multidimensional scaling, to control for population stratification.Table 4*Depressive disorderPAdj. R^2^βSE* **PPD vs all controls**0.1210.00282−1211.691782.234 PPD vs female controls0.1790.00266−1076.882802.015 **MDD vs all controls**0.5950.00008169.200318.049 Female MDD vs female controls0.6240.00005193.213393.920 Male MDD vs male controls0.8070.00011132.561542.234[^4]

4. Discussion {#sec0070}
=============

This study sought to better understand the relationship between circulating reproductive hormones and hippocampal volume via the application of polygenic epidemiology, whereby we estimated inter-individual variation in hormone levels based on genetic data, and tested how this affected hippocampal subfield volumes. We further investigated whether the same polygenic signature was associated with depressive disorders. Our results demonstrate a negative association between polygenic risk for estradiol levels and whole hippocampal volume, as well as the volume of many of its constituent subfields. However, this polygenic risk score did not predict the occurrence of depressive disorders. Previous literature has linked estradiol levels to whole hippocampal volume in humans, but this is the first to infer causality via polygenic scoring.

The hippocampus is a major target of estrogens in the brain due its high density of estrogen receptors which have the capacity to influence hippocampal volume through multiple actions, including altered gene expression, differential methylation of estrogen-responsive genes or by rapid-non genomic signaling pathways ([@bib0115]; [@bib0170]; [@bib0325]; [@bib0375]). Our results reveal an enrichment of estradiol's effect on 'neurogenic regions' of the hippocampus, namely the granule cell layer and molecular layer of the dentate gyrus. This suggests that polygenic risk for estradiol levels may confer some of its long-term influences on hippocampal volumes via moderating AHN. Changes in AHN have been associated with volumetric changes in the CA1 in rodents due to altered dendritic branching ([@bib0350]), which could feasibly also impact the CA4 region due to the presence of mossy fibers from dentate gyrus granule cells ([@bib0330]). In general, rodent studies indicate a proliferative effect of estradiol on dentate gyrus neural stem cells, but the majority of these studies focus on the very short-term effects of large changes in estradiol ([@bib0245]). Therefore, it is unclear what impact small, long-term differences in estradiol may have on the neurogenic potential of the hippocampus.

In the context of previous research, our findings support reports which have revealed an association between higher estradiol levels and smaller hippocampal volumes ([@bib0190]; [@bib0360]). It also agrees with the observation of reduced hippocampal volume during pregnancy in rats, when estradiol, alongside other sex hormones, is elevated ([@bib0155]; [@bib0315]). However, they are in contrast to other studies which have shown that higher estradiol concentration is associated with larger hippocampal volumes and propose a neuroprotective effect of estradiol ([@bib0025]; [@bib0030]; [@bib0160]; [@bib0215]). This discrepancy could be due to a number of different reasons. For example, the dynamic and acute effects of estradiol, which are more commonly studied, may be different to the more chronic, stable, and possibly lifetime effects captured by polygenic risk scores used in this study. Indeed, many of these studies quantified hippocampal volume in the post-menopausal period, following estradiol supplementation or alongside the menstrual cycle. Alternatively, as many previous studies have employed *in vitro* or animal model systems to draw conclusions about estradiol's effects, it may be the case that estradiol has different effects *in vivo* in humans. Finally, the majority of human studies conducted have focused on the impact of estradiol in either elderly, disease or medicated states. Therefore, it is difficult to discern what impact naturally occurring long-term differences in endogenous estradiol levels could have on the hippocampus.

Future research will be needed to better understand the differences in estradiol's acute and chronic actions in a variety of ages. Different stages of the lifespan are characterized by large changes in estradiol levels, including puberty, pregnancy and the menopause. Therefore, future work should aim to determine how applicable these findings are to these different contexts. Finally, this result does not necessarily reject the potential neuroprotective effects of estradiol in the menopause or in neurodegenerative diseases. In these cases, exogenous estradiol is used to rectify large deficits in endogenous estradiol which would not be present in the study population used here ([@bib0305]). Additionally, many of the benefits of exogenous estradiol in neurogenerative diseases are independent of hippocampal volume changes ([@bib0010]). Without fully understanding the cellular mechanism linking estradiol PRS to hippocampal volume observed in this study, we cannot say whether our findings are relevant to these therapeutic interventions.

We do not observe an association between PRSs for testosterone, progesterone or prolactin and hippocampal volume in our study. Compared to estradiol, the evidence for an association between hippocampal volume and these other reproductive hormones is far weaker. While there is some evidence that plasma testosterone correlates with hippocampal volume, this has only been conducted in males and tends to be in disease, elderly or medicated states ([@bib0145]; [@bib0265]; [@bib0420]). There are very few human studies investigating the role of progesterone or other progestins in hippocampal volume and many studies are confounded by concurrent changes in estradiol levels ([@bib0290]). Furthermore, it appears that endogenous progesterone compared to synthetic progestins have very different impacts on the brain ([@bib0085]). Like progesterone, the link between plasma prolactin and the hippocampus has not been properly investigated in humans. While there is a large body of work suggesting that prolactin can impact the rodent hippocampus at the cellular level ([@bib0070]; [@bib0080]; [@bib0260]), this does not appear to translate to any change in whole hippocampal volume ([@bib0390]). There is evidence from animal and cellular models that reproductive hormones can influence the hippocampus at the cellular level through changes in AHN, cell survival or branching ([@bib0085]; [@bib0260]; [@bib0300]), therefore it is possible that this may also occur in humans without affecting whole hippocampal volume.

In the context of MDD and PPD, PRS for estradiol did not directly relate to case-control status. This suggests that although estradiol could be one factor accounting for hippocampal volume reductions commonly observed in psychiatric patients, it does not directly predict case-control status. Consequently, it may be interesting to test if the estradiol PRS predicts other diseases in which the hippocampus has been linked, for example schizophrenia ([@bib0310]). This idea is supported by the observed link between estradiol PRS and hippocampal subfields such as the CA regions, subiculum and dentate gyrus in our study, which are commonly atrophied in a variety of psychiatric and degenerative disorders ([@bib0015]; [@bib0175]; [@bib0185]; [@bib0275]). Our negative result suggests that baseline estradiol levels may not play a causal role in depression, but this is not to say that estradiol is not involved in the development of depressive disorders. We acknowledge that inter-individual variation explaining estradiol levels in our base cohort may be different from those during pregnancy or other life events when plasma estradiol changes significantly. Additionally, environmental factors such as breastfeeding, parity or the drop following parturition may be more pertinent in moderating reproductive hormones in the peripartum period than genetic contributors ([@bib0050]; [@bib0345]; [@bib0440]). Our approach also utilized a stable, genetic predictor of hormone levels and therefore ignores any hormonal fluctuations that occur throughout the lifespan and are thought to contribute to depressive states ([@bib0165]). Furthermore, inter-individual variation in response to altered hormone levels, which are not considered here, have been shown to contribute to depressive disorders ([@bib0040]).

Despite the important findings detailed here, our study has three key limitations. Firstly, the accuracy of the PRS is subject to the power of both the original GWAS and our target datasets. Although the original GWAS was the largest to-date, it is likely still underpowered, and consequently our PRS may lack predictive power. Furthermore, the neuroimaging dataset and PPD subsets are small, which may mean we are unable to detect smaller effect sizes in our sample. In addition, our neuroimaging cohort consisted of both healthy and depressed individuals. Although we detected no differences in volume between those who had and had not been on antidepressants within the last six months, we were underpowered to test the effects of individual drug types and treatment durations, which have been linked to changes in hippocampal volume ([@bib0045]). Additionally, we lacked information on factors such as menstrual stage, menopause or hormonal medications, which may also impact hippocampal volume ([@bib0025]; [@bib0030]). Secondly, although PRSs are commonly used in Mendelian randomization designs and genetic epidemiology ([@bib0120]; [@bib0275]; [@bib0285]), they may be subject to the effects of horizontal pleiotropy; whereby a subset of SNPs included in the PRS predict variance for another related trait, driving the observed association ([@bib0120]). Although horizontal pleiotropy is possible, it's important to note that at the protein level, estradiol is correlated with testosterone ([@bib0320]), which did not predict hippocampal volume in our study; supporting the view that the effect may be uniquely related to estradiol. In the future, inference of causality can be made more certain once more powerful GWASs are performed and replicable genome-wide significant association hits can be used as an instrumental variable to probe the direction of association between estradiol and hippocampal volume. Finally, the definition of PPD within this study was made retrospectively using a subset of the MDD cohort. We therefore may be missing other PPD cases due to insufficient information (e.g. where pregnancy aligned to the third most severe depressive episode, which was not captured). Additionally, for our PPD analysis we used a control population which did not exclude women who had not experienced a pregnancy and therefore could not have experienced PPD. We did this primarily due to a small sample size and missing data in our control sample on whether females had experienced a previous pregnancy. Subsequently, because the risk for PPD is relatively low on the population level, we included all female RADIANT controls in order to achieve the best power possible. We acknowledge that screened controls would have made for a more ideal comparison group.

5. Conclusions {#sec0075}
==============

Our study employed novel genetic and neuroimaging analyses which provide new insight into the regulation of hippocampal volume by estradiol. Our work suggests genetic risk for higher estradiol levels predict smaller hippocampal volumes, possibly mediated via changes to AHN in the neurogenic regions of the hippocampus. Genetic risk for higher estradiol levels was not, however, associated with risk for developing MDD or PPD. Future studies should aim to replicate our findings in larger samples, test the generalizability of the findings outside of the European population, and examine whether estradiol's effects on the hippocampus moderate risk for diseases other than depression.
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[^1]: Abbreviations: Antidepressants: Has taken antidepressant drugs within the past 6 months; PPD: postpartum depression; MDD: major depressive disorder.

[^2]: The optimal threshold is defined as the p-value threshold for the group of SNPs which produces the best-fit PRS for each regression. Whole hippocampal volume was corrected for intracranial volume, age, sex and depression status. All regression analyses include seven population covariates, derived from multidimensional scaling, to control for population stratification. Associations which survive FDR corrections are indicated with \*. Abbreviations: PRS: polygenic risk score; nSNPs: number of SNPs included in the optimal PRS; p-value: uncorrected p-value; q-value: FDR-corrected p-value; R^2^: amount of variance explained by the respective optimal PRS; *β*: regression coefficient; SE: standard error.

[^3]: Each hippocampal volume was adjusted for intracranial volume, age, sex and depression status. All regression analyses include seven population covariates, derived from multidimensional scaling, to control for population stratification. Associations which survive FDR corrections are indicated with \*. Abbreviations: p-value: uncorrected p-value; q-value: FDR-corrected p-value; R^2^: amount of variance explained by the respective optimal PRS; *β*: regression coefficient; SE: standard error.

[^4]: Abbreviations: PRS: polygenic risk score; Adj. R^2^: amount of variance explained by the respective optimal; *β*: regression coefficient; SE: standard error; PPD: postpartum depression; MDD: major depressive disorder.
